Why Is Moderna Stock Surging? Cancer Vaccine Breakthrough Explained

Moderna (NASDAQ: MRNA) made history on August 19, 2026, with its largest single-day stock surge ever. Shares rocketed approximately 177%, closing at $174.38 after positive trial results for its experimental skin cancer vaccine .

What Caused the Surge?

The dramatic spike was driven by promising Phase 3 clinical trial results for intismeran, a personalized mRNA skin-cancer vaccine developed jointly with Merck . The trial met its primary endpoint of recurrence-free survival for high-risk melanoma patients when combined with Merck's immunotherapy Keytruda .

The combination regimen also reduced the risk of cancer spreading to distant parts of the body. These results build on positive Phase 2 trial data from earlier this year .

What Makes This Vaccine Different?

Every tumor has a unique set of mutations. Moderna's vaccine is designed to target the specific mutations in each patient's tumor, creating a truly personalized treatment . The idea is to train the immune system to recognize and kill those unique cancer markers.

How Significant Is This?

Melanoma is the deadliest form of skin cancer, causing the majority of skin cancer deaths. Dr. Jane Healy, Merck's head of oncology early development, called the results "very exciting" and "clinically meaningful" .

The Phase 3 results are a make-or-break event for Moderna's stock, according to analysts. The company's valuation now reflects expectations that the personalized cancer vaccine could eventually work across multiple types of cancers, not just melanoma .

Future Plans

Moderna and Merck are studying the vaccine in several trials across other tumors, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma . Management plans to submit the clinical data to the FDA and international regulators for potential approval paths .

What to Watch Next

Bank of America upgraded Moderna to Neutral from Underperform, raising its price target to $170 from $40 . A key analyst noted that a hazard ratio of 0.6 to 0.7 at an upcoming medical meeting, likely the European Society for Medical Oncology conference, would be needed to turn more positive .